An imbalance between production and clearance of soluble amyloid-β (Aβ) initiates the pathological process in sporadic Alzheimer's disease (AD). Aβ-specific antibodies seemed promising as therapeutic option in AD mouse models. In patients, however, vascular side-effects and Aβ-antibody complex-induced microglial and/or perivascular macrophage inflammatory responses were encountered.
Introduction
Cerebral accumulation of the amyloid-β (Aβ) peptide in extracellular deposits called amyloid plaques is a pathological hallmark of Alzheimer's disease (AD). Patients with familial early-onset AD (EOAD) either carry mutations in the Aβ region of the amyloid precursor protein (APP), or in other genes related with Aβ processing (PSEN1, PSEN2) (Benilova et al., 2012; Karran et al., 2011) , which suggests that Aβ plays a key role in AD pathogenesis, as exemplified by subsequent neurofibrillary tangle formation, neuroinflammation, synapse loss, neuron death and ultimately, dementia (Hardy, 2009 ). On the other hand, the ε4 allele of the APOE gene is established as the major risk factor for developing late-onset sporadic AD (LOAD), the most prevalent form of the disease (Hardy, 2009) .
Increased local levels of Aβ, resulting from an imbalance between Aβ production and clearance may lead to formation of Aβ oligomers with synaptotoxic and neurotoxic properties (Walsh et al., 2002; Lesné et al., 2006) , both early steps in the sequence of events leading to tau and AD pathology in LOAD (Mawuenyega et al., 2010; Eikelenboom et al., 2006) . Adult mouse astrocytes were shown to degrade Aβ (WyssCoray et al., 2003) , and also adult human astrocytes as well as microglia, although with different uptake efficacy, ingest Aβ oligomers and In addition, high-throughput genotyping analyses also identified the APOJ gene, which encodes apolipoprotein J (apoJ; clusterin), as a genetic determinant for LOAD in two independent genome-wide association studies (Harold et al., 2009; Lambert et al., 2009) . ApoJ is thought to act as an extracellular chaperone with the capacity for interacting with a wide range of molecules (Leeb et al., 2014) , including the fluid phase complement C5b-7 complex, thereby preventing insertion in the cell membrane and formation of the membrane attack complex on bystander cells (Jenne and Tschopp, 1992) . Although some have pointed out that apoJ expression facilitates, but is not required for Aβ fibril (amyloid) formation (DeMattos et al., 2002) , others have shown that apoJ inhibits Aβ fibril formation in vitro and, because of its chaperone function, promotes the clearance of protein aggregates via either diffusion to the CSF (Ghiso et al., 1993) or ISF (Wojtas et al., 2017) , or through endocytosis (Cascella et al., 2013) .
Apolipoproteins E and J both are found in fibrillar as well as diffuse Aβ plaques, linked to early pathological features of AD, before tau-related changes become apparent (Zhan et al., 1995) . In combination with results from AD mouse model studies (DeMattos et al., 2002) , this suggests that apoE and apoJ play an important role in the dynamic balance between Aβ production and Aβ clearance from the brain. We previously assessed the effects of these apolipoproteins on Aβ uptake by human glial cells, and found Aβ clearance by adult human glial cells to be negatively affected by apoE and apoJ (Mulder et al., 2014) .
The aim of the current study was to investigate the effects of scFvh3D6 on Aβ uptake and Aβ-mediated astrocyte activation and toxicity, in the absence and presence of apoE and apoJ. We first compared the effects of scFv-h3D6 and its full-length mAb. Next, full-length plasmaderived apoE and apoJ, and also apoE and apoJ mimetic peptides (MP) that retain essential structures within these apolipoproteins for binding to other molecules, were tested alongside scFv-h3D6. The apoE-MP is composed of the receptor binding site within apoE and a lipid-associating-domain emulating its lipid binding site (Sharifov et al., 2011; Handattu et al., 2013) . Since sequence differences among apoE isoforms are located outside of these moieties, this mimetic peptide is a common fragment of all of them. This apoE-MP stimulates apoE synthesis in astrocytes in vitro, crosses the BBB (0.13% of injected dose in mice), and is able to recirculate. Moreover, in vivo the apoE-MP was found to reduce Aβ plaque deposition, microglial and astrocytic activation and associated release of TNF-α and IL-6 in the APP/PS1 Alzheimer mouse model (Handattu et al., 2013) . The apoJ-MP, designed for treatment of atherosclerosis, is a 10-residue D-peptide corresponding to the 6 th predicted G* helix of apoJ (Navab et al., 2005) . This apoJ-MP is effective in animal models through enhancement of the anti-inflammatory properties of HDL (Navab et al., 2005) and was proposed as therapy for inflammatory disorders other than atherosclerosis, as well (Navab et al., 2008) .
In the present study scFv-h3D6 was found to strongly inhibit the uptake of potentially toxic Aβ oligomers by adult human astrocytes in vitro. Although this effect is similar to that of full length mAb-h3D6, scFv-h3D6 has the advantage that it lacks the 3D6 Fc-tail, and is not expected to elicit a Fc-receptor -mediated microglial inflammatory response. Full-length apoE and apoJ and the apoE-MP and apoJ-MP also inhibited astrocytic Aβ uptake. When tested either alone, or in combinations, the apoE-MP was consistently found to inhibit the Aβ oligomerinduced IL-6 and MCP-1 release. This opens possibilities to consider small molecules like the apoE-MP as therapeutic to prevent the inflammatory response associated with AD pathology, or for combined use with Aβ-specific scFvs.
Materials and methods

Primary human astrocyte cultures
Brain specimens for cell isolations were obtained at surgery through cooperation with the Neurosurgery Department of VU university medical center Amsterdam (VUmc). Patients underwent focal cortical resection for drug resistant epilepsy. The tissue obtained, had to be removed to reach the epileptic focus and was not needed for diagnostic purposes. Patients gave written informed consent and permission for the use of human brain tissue for in vitro research in compliance with the Declaration of Helsinki, was granted by the Medical Ethics Committee at VUmc. Adult primary human astrocytes were isolated from normal temporal cortex specimens from 5 patients (Table 1) , as described before (Nielsen et al., 2009; Nielsen et al., 2010; Mulder et al., 2014) .
Aβ 1-42 Preparations
Aβ 1-42 oligomers and fibrils were prepared and characterized by Western blotting as described (Nielsen et al., 2009; Nielsen et al., 2010) . In short, Aβ 1-42 (Bachem) was dissolved in hexafluoro-isopropanol (Fluka) to obtain a monomeric Aβ 1-42 solution, which subsequently was aliquoted, nitrogen-flow dried and stored at −80°C until further use. To obtain fluorescent (FAM labeled) Aβ 1-42 preparations enriched in oligomers and fibrils, aliquots of 100 μg of Aβ were resuspended in 20 μM FAM labeled Aβ 1-42 (Anaspec) dissolved in DMSO, resulting in an Aβ concentration of 2.5 mM, and further diluted (100 μM) and incubated, either in phenol-red free DMEM (at 4°C for 24 h) to obtain oligomers, or in HCl (10 mM) (at 37°C for 24 h) to form fibrils. Aβ oligomerization state of the preparations was analyzed by Western-blot (Fig. 1A) , essentially as described (Nielsen et al., 2010) .
Humanized monoclonal antibody 3D6
Recombinantly expressed humanized bapineuzumab (3D6; huIgG1) was kindly provided by Dr. Mario Losen (Division Neuroscience, Maastricht University, The Netherlands).
ScFv-h3D6 expression and purification
The sequence of the mAb h3D6.v2 was used to construct a synthetic gene consisting of the V H and V L domains of the humanized monoclonal antibody, fused by a (Gly 4 Ser) 3 linker (Marín-Argany et al., 2011) . In this work, scFv-h3D6 was expressed using pET28a (+) vector and Escherichia coli BL21 strain. Induction with 0.5 mM IPTG (isopropyl β-Dthiogalactopyranoside) was performed at D 600 = 0.7 and incubation in the shaker at 20°C for 18 h. After three freeze-thaw cycles, the cellular pellet was sonicated for 5 min, at 70% duty cycle and output 9 (Sonifier 450, Branson). The protein was obtained by solubilizing the insoluble fraction in denaturing buffer (100 mM Tris-HCl, 10 mM GSH, pH 8.5, and 8 M urea) and refolding by dilution (1:10) in ice-cold refolding buffer (100 mM Tris/HCl, 100 mM L-arginine and 0.15 mM GSSG, pH 8.5) for 48 h. Cationic exchange chromatography (Resource S6, GE Healthcare) using 5 mM Na 2 HPO 4 , pH 6.5, as running buffer and a gradient up to 150 mM NaCl in the same buffer was used to completely purify the protein and also fractionate the native state and the disulphide scrambled forms of scFv-h3D6. Putative lipopolysaccharide contaminations were removed from the protein by using Detoxi-Gel Endotoxin Removing columns (Thermo Scientific). The buffer was changed to PBS using PD-10 Desalting Columns (GE Healthcare), and protein aliquots (150 μl) were stored at −20°C until use. The molecular mass of the different batches of purified protein was confirmed by MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) spectrometry, and the protein concentration was determined from its absorbance at 280 nm using an absorbance coefficient of 1.06 UA/cm for a 1 mg/ml native scFv-h3D6 solution .
Apolipoproteins and apolipoprotein-mimetic peptides
ApoE (plasma derived; isolated from human VLDL) was obtained from rPeptide (Bogart, GA; cat. #: A-2001-1) and ApoJ was isolated in house from human plasma by affinity chromatography, as described (Jongbloed et al., 2014) .
The apoE-MP, composed of the receptor binding site (residues 141-150) within apoE and a Class A lipid-associating-domain similar to the lipid binding site of apoE (Sharifov et al., 2011; Handattu et al., 2013) , and the apoJ-MP, composed of D-isomers of residues 113 to 122 (6 th predicted G* helix of the 17 potential G* amphipathic helices in the mature apoJ protein) (Navab et al., 2005) , were synthetized by Caslo ApS (Lyngby, Denmark).
Cell treatment and flow cytometry
Isolated astrocytes were cultured in medium containing a mixture of DMEM and HAM-F10 (Gibco) (1:1) supplemented with 10% (v/v) fetal calf serum (Hycult), L-glutamin (2 mM; Gibco), penicillin (100 IU/ml and streptomycin (50 μg/ml) (both Gibco) at 37°C and 5% CO 2 (Nielsen et al., 2009) . Astrocytes up to passage 5 were used for experiments and plated at a density of 25,000-50,000 cells per well in a 24-well plate. Cells were allowed to adhere for 48 h, whereafter medium was removed and replaced by serum free medium, containing either oligomers, or fibrils of fluorescently labeled Aβ (10 μM final concentration), alone or together with the different compounds (mAb-h3D6/scFv-h3D6/apoE/ apoE-MP/apoJ/apoJ-MP) without any previous co-incubation. The intact mAb and scFv anti-Aβ were added to the cells at 1 μM (mAb-h3D6), and 4 μM (scFv-h3D6) final concentrations, respectively. The 4-fold difference in concentration of mAb-h3D6 and scFv-h3D6 used, was based on the difference in number of antigen binding sites and the stability of both molecules. ApoE and apoJ (full-length or mimetics) were added at final concentration of 0, 0.1 and 1 μM, as in previous studies (Mulder et al., 2014) .
The cells were harvested after 18 h of treatment and cellular uptake of FAM-labeled Aβ 1-42 was quantified, using flow cytometry as described before (Nielsen et al., 2009; Nielsen et al., 2010; Mulder et al., 2014) . In addition, cell-free conditioned culture medium was collected, centrifuged (300 ×g for 5 min) and stored at −20°C until further analysis. Cells were rinsed with PBS and incubated (2 min.) with trypan blue (0.2%; w/v) in PBS in order to quench the signal of extracellular bound Aβ oligomers or Aβ fibrils. The cells were harvested using 0.25% trypsin, followed by three washes in cold FACS buffer (0.25% BSA in PBS). The percentage Aβ-positive astrocytes, 10,000 counted cells per condition, was quantified using the FACS Calibur (BD Biosciences, San Jose, CA) with the CellQuest software. Cells were gated based on morphological appearance (forward and side scatter) to count all viable cells and exclude cellular debris and dead cells. For visualization purposes, the results on uptake of Aβ alone were set to 100% and the effects of different treatments on Aβ uptake were normalized to Aβ uptake alone.
Enzyme linked immuno-sorbent assays for IL-6 and MCP-1
To determine astrocytic pro-inflammatory activation and production and secretion of inflammatory factors, conditioned medium from Demographics of patients who underwent surgery for therapy resistant epilepsy. Normal neocortex specimens removed to reach the epileptic focus were used to isolate astrocytes for the Aβ uptake experiments.
the astrocyte cultures used for flow cytometry analyses was collected and analyzed for MCP-1 release, using the Human CCL2/MCP-1 DuoSet enzyme linked immuno-sorbent assay (ELISA) (R&D Systems), and IL-6 release, assayed with the Pelipair IL-6 ELISA kit (Sanquin). Results are presented as % of MCP-1 or IL-6 release compared to non-treated cells.
Cytotoxicity assay
In order to test toxicity of the compounds used in the current study, LDH levels of the collected supernatants were determined by Pierce LDH cytotoxicity assay kit (ThermoScientific). Results are expressed as percentage considering non-treated cells as 100% viable.
Statistics
Differences among the various treatments were assessed with a paired t-test using raw data. Correlations were investigated using the Pearson correlation test. All data were expressed as means ± SEM values and a p value of < 0.05 was considered to reflect statistical significance.
Results
Aβ uptake and Aβ-induced inflammation in primary human astrocytes
The uptake capacity of adult human astrocytes for Aβ oligomers and Aβ fibrils (Fig. 1A) was determined by flow cytometry, after quenching the signal from extracellularly attached Aβ using trypan blue. The percentage of astrocytes that ingested Aβ was higher when exposed to Aβ oligomers (42.7% ± 7.5) compared to Aβ fibrils (3.0% ± 0.6) (Fig. 1B) , in line with earlier findings.
Human astrocytes secreted higher levels of IL-6 (27.8 -fold) and MCP-1 (2.4 -fold) upon exposure to Aβ oligomers, but no effect on activation was found for exposure to Aβ fibrils (1.2 and 1.1 folds, respectively; Fig. 1C-D) .
Effects of mAb-h3D6 and scFv-h3D6 on Aβ uptake and on Aβ-induced inflammation
First, we tested if the single-chain variable fragment (scFv-h3D6) derived from the humanized monoclonal antibody bapineuzumab, has similar effects on Aβ oligomer and Aβ fibril uptake by primary human astrocytes, as intact mAb-h3D6. We found mAb-h3D6 and scFv-h3D6 to reduce the % Aβ oligomer uptake by human primary astrocytes to 19.3% ± 5.6 and 8.6% ± 2.7 of uptake in the absence of either mAb-or (Table 1) , are presented as means and standard deviation (whiskers).
# p < 0.05 compared to untreated cells, ⁎ p < 0.05 compared to Aβ oligomer or Aβ fibril exposed cells. * or # p < 0.05, ** or ## p < 0.01, *** or ### p < 0.001.
scFv-h3D6 (set at 100%), respectively. No significant effect of either mAb-h3D6 (153.7% ± 25.1) or scFv-h3D6 (84.4% ± 18.9) on Aβ fibril uptake was observed, when compared to uptake of Aβ fibrils alone (set at 100%; Fig. 2A ). No significant effects of either mAb-h3D6 or scFv-h3D6 on Aβ oligomer-induced IL-6 and MCP-1 release were observed (Figs. 2B-C) . Whereas Aβ fibrils alone had no stimulatory effects on either MCP-1, or IL-6 secretion by the astrocytes, the combination of Aβ fibrils and scFvh3D6 significantly increased the secretion of MCP-1 (p = 0.027, compared to effects of Aβ fibrils), and a trend (p = 0.14) towards increased IL-6 secretion was observed (Fig. 2B-C) .
Taken together, both mAb-h3D6 and scFv-h3D6 reduced the uptake of Aβ oligomers, without affecting the Aβ oligomer-induced IL-6 and MCP-1 release by the astrocytes, but have no significant effect on Aβ fibril uptake in our test conditions.
Effects of mimetic peptides and full-length apoE and apoJ on Aβ uptake
We previously found apolipoproteins E and J to reduce the uptake of Aβ oligomers and Aβ fibrils (Mulder et al., 2014) . Here, we compare the effect of apoE-MP and apoJ-MP with that of the full-length plasmaderived apolipoproteins on Aβ uptake by primary adult human astrocytes, as well as on the Aβ-induced activation of the astrocytes, in vitro.
Aβ oligomers and Aβ fibrils (10 μM) were applied to the cells simultaneous with either full-length apoJ or apoE, or apoJ and apoE mimetic peptides. ApoE-MP and apoJ-MP were tested in concentrations ranging from 0.01 to 1 μM, similar to the concentration range used for full-length apoE and apoJ in previous studies (Mulder et al., 2014; Nielsen et al., 2010) .
Apolipoproteins E and J, full length as well as MP, inhibited Aβ oligomer uptake, in the highest concentration (1 μM apolipoprotein variants vs 10 μM Aβ; ratio 1:10) tested (Fig. 3) . Full-length apolipoproteins were more potent in reducing Aβ oligomer uptake than the mimetic peptides. ApoE and apoJ at a concentration of 1 μM reduced Aβ oligomer uptake by astrocytes to 43.4% and 10.8%, respectively (Fig. 3A-C) , whereas apoE-MP and apoJ-MP reduced uptake to 73.7% and 72.8%, respectively (Fig. 3B-D) . Except for the significant reduction of Aβ fibril uptake in the presence of apoE-MP at 1 μM (Fig. 3B) , no significant effects of apoE and apoJ, as well as their MP, were seen on Aβ fibril uptake.
3.4. Effects of mimetic peptides and full-length apoE and apoJ on Aβ-induced secretion of IL-6 and MCP-1
To determine if inhibition of Aβ uptake by the astrocytes also leads to changes in their pro-inflammatory response induced by Aβ aggregates, the effect of apolipoproteins and mimetic peptides on the Aβ aggregate-induced IL-6 and MCP-1 release was determined.
Apolipoprotein E and apoE-MP (at 1 μM) exerted strong down-regulatory effects on Aβ oligomer-induced pro-inflammatory cytokine release. Full length apoE and apoE-MP to a large extent abolished the Aβ oligomer-induced secretion of IL-6 by astrocytes (from a 5-fold increase to a two-fold increase, compared to IL-6 released by medium treated astrocytes; Fig. 4A-C) . ApoE-MP also clearly inhibited the Aβ oligomerinduced MCP-1 release, whereas no significant effects of full length apoE were observed (Fig. 4B-D) . No such decrease in IL-6 or MCP-1 levels was seen with either full length or MP apoJ (Fig. 4E-F and G-H) . Instead, full-length apoJ enhanced the Aβ oligomer, and also Aβ fibril, induced IL-6 and MCP-1 release at the highest dose assayed (1 μM) (Fig. 4E-F) . ApoE and apoE-MP had no significant effect on Aβ fibrilinduced IL-6 release by the astrocytes, neither did apoJ-MP (Fig. 4A-C) .
Combined effects of scFv-h3D6, apoE-MP, and apoJ-MP on Aβ uptake and Aβ-induced secretion of IL-6 and MCP-1
Because apoE-MP and apoJ-MP had similar effects on Aβ uptake and Fig. 2 . Comparison of the effects of the full-length mAb-h3D6 vs scFv-h3D6 on adult human astrocytes. (A) Effects on the uptake of Aβ oligomers and Aβ fibrils by adult human astrocytes. Intact mAb-h3D6 as well as scFv-h3D6 inhibit the uptake of Aβ oligomers, but have no effect on Aβ fibril uptake. The % fluorescent Aβ-positive cells upon incubation with either Aβ oligomers, or Aβ fibrils, was set at 100%. Effects on the release of IL-6 (B) and MCP-1 (C), as indicators of proinflammatory activation. The IL-6 and MCP-1 release by treated cells was compared to baseline levels of medium-treated cells (set at 100%; solid line). Results from three independent experiments performed with astrocyte cultures from three different donors are presented as means and standard deviation. Aβ-mediated astrocyte activation as full-length apoE and apoJ, we used the MPs in further studies to determine their effect in combination with scFv-h3D6. Either Aβ oligomers or Aβ fibrils were added (10 μM) to the human astrocytes simultaneously with different combinations of scFvh3D6, apoE-MP or apoJ-MP (all at 1 μM), and effects on the uptake of Aβ oligomers and Aβ fibrils, as well as on the Aβ-induced activation of the astrocytes were determined. ScFv-h3D6 and apoE-MP significantly inhibited the uptake of Aβ oligomers (Fig. 5A) . The uptake of Aβ fibrils was inhibited by apoE-MP only (Fig. 5B) . Combinations of either apoE-MP or apoJ-MP and scFvh3D6 did not inhibit Aβ oligomer uptake to a larger degree than scFvh3D6 alone (Fig. 5A) . Except for apoE-MP alone, none of the compounds, either alone or in combination, affected Aβ fibril uptake (Fig. 5B) .
The activation of astrocytes by Aβ oligomers was not affected by the presence of either scFv-h3D6 or apoJ-MP, as judged from the unchanged levels of secreted IL-6 and MCP-1 (Fig. 5C and E) . In contrast, apoE-MP reduced IL-6 and MCP-1 release to levels similar to those secreted by untreated cells (119.8% and 85%, respectively; Fig. 5C and E), as was previously observed with the full-length apoE (Figures 4AB). When apoE-MP was added to the cell culture in combination with scFvh3D6, the lowering effects of the apoE-MP on IL-6 and MCP-1 release (138.0% and 94.4%, respectively) remained similar ( Fig. 5C and E) , which demonstrates that the anti-inflammatory effect of apoE-MP is not abrogated in the presence of scFv-h3D6.
Whereas Aβ fibrils alone did not significantly induce activation of the astrocytes (Fig. 5D and F) , Aβ fibrils in combination with scFvh3D6, induced the secretion of IL-6 (Fig. 5D ), an effect that was counteracted by the presence of apoE-MP, but not of apoJ-MP (Fig. 5D) , suggesting different functional properties of the apoE-MP and apoJ-MP.
To investigate if variations in cell viability account for the observed effects, LDH release from the exposed astrocytes was determined in the culture supernatants collected after 18 h. No differences in LDH release between medium-treated cells and astrocytes treated with scFv-h3D6, apoE-MP and/or apoJ-MP at 1 μM concentrations, were observed (Fig. 6 ).
Discussion
Long term exposure to increased levels of Aβ may lead to impairment of astrocyte and neuronal functioning and to synaptic changes, which are early events in AD etiology (Hardy, 2009) . Whereas Aβ production rates were similar to those in cognitively normal controls in a metabolic labeling study, clearance rates for both Aβ 1-42 and Aβ were impaired in AD (Mawuenyega et al., 2010) . Clearance mechanisms include diffusion towards CSF and choroid plexus, transport across the BBB, and uptake and lysosomal degradation by glial cells (Thal, 2012; Lai and McLaurin, 2012) . Clearance of Aβ from the brain Fig. 3 . Comparison of the effects of full-length apolipoproteins and mimetic peptides on Aβ oligomer and Aβ fibril uptake by primary human astrocytes. Aβ oligomers (black) and Aβ fibrils (grey) were added to the astrocytes either in the absence or the presence of (A) full-length apoE, (B) ApoE-MP, (C) full-length apoJ, or (D) ApoJ-MP. The Aβ oligomers and Aβ fibrils (final concentration of 10 μM) were added to the cell culture simultaneously with the apolipoproteins and mimetic peptides, tested at a 10-fold dilution range from 0.01 to 1 μM. Uptake of Aβ alone was set to 100%. Results from five independent experiments performed with astrocyte cultures from five different donors (Table 1) are presented as means with standard deviation. * p < 0.05, ** p < 0.01, *** p < 0.001. parenchyma by astrocytes seems impaired in LOAD, as astrocytes from AD patients have lost their capacity to upregulate SCARB1, a scavenger receptor involved in Aβ uptake, in response to Aβ fibrils in vitro (Mulder et al., 2012) , and astrocytes from aged 5xFAD Alzheimer model mice exhibit reduced SCARB-1 expression and impaired uptake of Aβ (Iram et al., 2016) . Several in vitro and animal studies have indicated that soluble, oligomeric Aβ levels correlate with neurodegeneration and cognitive deficits, and thus that oligomeric and protofibrillar forms of Aβ should be considered as crucial toxic species (Wang et al., 1999; Lesné et al., 2006; Walsh et al., 2002) .
Thus, an imbalance between production and clearance of Aβ can have direct effects on neuronal cells, but also on astrocytes that are triggered by oligomeric Aβ 1-42 to release of inflammatory mediators (White et al., 2005) . In addition, it can lead to formation of fibrillary Aβ deposits and the initiation of neuroinflammatory processes, associated with clusters of activated microglia that release pro-inflammatory cytokines that, in turn, can activate astrocytes to produce cytokines and acute phase proteins (Veerhuis et al., 2005; Eikelenboom et al., 2006; Sokolova et al., 2009) .
Astrocytes are the predominant cell type in the brain, that form an extensive network using calcium and sodium signaling for communication, and contribute to blood flow regulation and brain metabolism through end-feet on brain capillaries. Astrocytes present at synapses take up glutamate and buffer extracellular potassium, but excess glutamate released by acutely activated neuronal cells triggers astrocytes to convert glycogen into lactate, that, in turn, is used by the active neurons as aerobic substrate (Pellerin et al., 2007) . Recent studies have indicated that astrocytes are highly phagocytic and participate in normal synapse pruning and turnover, thereby modulating synaptic transmission and plasticity. This process is ApoE isoform dependent (Chung et al., 2016) .
Astrocytes also move towards Aβ deposits and ingest the Aβ (WyssCoray et al., 2003) . As a downside of this, Aβ binding to and uptake by astrocytes down-regulates expression of the glutamate receptor GLT1 on astrocytic end feet in the synaptic area, which affects glutamate reuptake and synaptic glutamate levels, and triggers excitotoxic pathways (Matos et al., 2008; Talantova et al., 2013) . Moreover, because astrocytes are inefficient in digesting the Aβ, uptake was suggested to induce lysosomal dysfunctioning, whereafter the astrocytes, as a protective measure, release toxic N-terminal-truncated Aβ containing microvesicles that, in turn, induce apoptosis in cortical neurons in vitro (Söllvander et al., 2016) .
Therapeutic strategies for LOAD aimed at increasing the uptake of Aβ by microglia, have yielded disappointing results. Despite positive effects on Aβ load and cognition, passive as well as active immunization against Aβ generated side effects including meningoencephalitis and vasogenic edema (Montoliu-Gaya and Villegas, 2016; Bohrmann et al., 2012; Ostrowitzki et al., 2012) . These effects were related to FcγR-dependent activation of glial cells. Therefore, we engineered a single chain antibody fragment (scFv-h3D6) composed of the variable domain of the heavy chain linked to the variable domain of the light chain of bapineuzumab (Marín-Argany et al., 2011; Rivera-Hernández et al., 2013) . This scFv-h3D6 was found to be neuroprotective in vitro (SH-SY5Y cells exposed to Aβ) and in vivo reduced Aβ load and ameliorated learning and memory deficits in 3xTg-AD mice. In addition, intraperitoneal scFv-h3D6 administration reduced the raised apoE and apoJ levels in the 3xTg-AD mice, to normal (Esquerda-Canals et al., 2013; Giménez-Llort et al., 2013) .
In the current study we investigated the effects of scFv-h3D6 alone or in combination with mimetic peptides (MP) of apoE and apoJ on Aβ uptake by adult human astrocytes and on Aβ-mediated astrocyte activation, with the ultimate aim to design therapeutic compounds that enhance Aβ oligomer clearance without initiating an inflammatory reaction. Adult human astrocytes were found to more readily ingest Aβ oligomers than Aβ fibrils, in line with our previous findings (Mulder et al., 2014; Nielsen et al., 2010 Nielsen et al., , 2009 . We next compared full-length mAb-h3D6 (bapineuzumab) and its single-chain variable fragment (scFv-h3D6) for effects on Aβ uptake by adult human astrocytes, at antibody: Aβ ratios of 1:10 and 4:10, respectively. Whereas both mAbh3D6 and scFv-h3D6 reduced Aβ oligomer uptake, scFv-h3D6 (reduction) and mAb-h3D6 (increase) tended to have opposing effects on Aβ fibril uptake by the primary human astrocytes. It is tempting to speculate that full-length mAb may have intercalated within the Aβ fibrils, which generated smaller sized oligomeric and monomeric Aβ, that can be ingested by the cells through scavenger receptors, whereas the scFvh3D6 lacks this potential and prevents interaction of Aβ oligomers as well as fibrils with scavenger receptors involved in uptake and degradation. When tested alone, Aβ oligomers, but not Aβ fibrils, were found to induce secretion of pro-inflammatory factors IL-6 and MCP-1 by the adult human primary astrocytes in vitro (18 h; Fig. 1 ), in line with rat astrocyte studies showing immediate early effects of Aβ oligomers, but delayed (> 24 h) effects of Aβ fibrils, on cytokine release (White et al., 2005) . Neither full length, nor scFv-h3D6, affected Aβ oligomerinduced IL-6 and MCP-1 cytokine release in the present study. It remains elusive, why scFv, and not full length 3D6, in combination with Aβ fibrils initiated cytokine release ( Fig. 2B and C) . Allelic variation in apolipoprotein E is the strongest risk factor for LOAD, however, another lipid transporter, apolipoprotein J, also is clearly implicated in AD, as APOJ (CLU) was repeatedly identified in high-throughput genotyping analyses as a genetic determinant of LOAD (Harold et al., 2009; Lambert et al., 2009) .
Astrocytes can secrete apolipoproteins E and J (LaDu et al., 2001; Bruinsma et al., 2010) , that probably exert beneficial effects in Aβ clearance, by keeping the Aβ soluble, which enables transport towards CSF and/or blood (Ghiso et al., 1993; Bell et al., 2007; Verghese et al., 2013) , and, in addition, prevents Aβ oligomer uptake by the astrocytes and associated toxic effects (Bruinsma et al., 2010) . ApoJ -Aβ complexes are readily detectable in cerebrospinal fluid (Ghiso et al., 1993; unpublished results) , and apoJ was found to increase Aβ clearance from the brain and interstitial fluid in transgenic mouse models of AD crossed to CLU knockout mice (Bell et al., 2007; Wojtas et al., 2017) .
ApoE was shown to exert anti-inflammatory effects, as it downregulated lipopolysaccharide (LPS)-induced CNS cytokine production in mice (Lynch et al., 2001) . Glial cells cultured from apoE-knockout mice have an enhanced potential to produce pro-inflammatory markers in response to Aβ treatment. Receptor associated protein (RAP), an inhibitor of apoE receptors with highest affinity for low density lipoprotein receptor-related protein 1 (LRP1), interfered with Aβ-induced glial activation, suggesting that this effect was mediated through LRP1 (LaDu et al., 2001 ). The prominent anti-inflammatory effects of apoE have led researchers to develop small peptides containing the receptor binding domain of apoE as possible therapeutic, mimicking the antiinflammatory activity of apoE. Proof of concept for using apoE-mimetic peptides (MP) came from studies in which apoE-MP administered to transgenic mice carrying three human APP mutations (SwDI-APP/ NOS2(−/−)),leading to high Aβ40 levels, reduded Aβ load, tau pathology and IL-6 levels (Vitek et al., 2012) , and administration to APP/ PS1ΔE9 mice significantly reduced the numbers of activated microglia Fig. 4 . Comparison of the effects of full-length apolipoproteins and mimetic peptides on Aß-induced IL-6 and MCP-1 release by primary human astrocytes. Astrocytes were exposed to Aβ oligomers (black) or Aβ fibrils (grey), either in the absence or presence of (A-B) full-length apoE, (C-D) ApoE-MP, (E-F) full-length apoJ, or (G-H) ApoJ-MP. IL-6 and MCP-1 release by treated cells was compared to baseline levels secreted by cells exposed to medium alone (set at 100%; solid line). Results from five independent experiments performed with astrocyte cultures, each from a different donor (Table 1) , are presented as means with standard deviation. # p < 0.05 compared to untreated cells, * p < 0.05 compared to Aβ oligomer or Aβ fibril exposed cells, ** p < 0.01. Fig. 5 . Effects of scFv-h3D6, apoE-MP and apoJ-MP, alone or combined, on the uptake of Aβ oligomers and Aβ fibrils as well as on the release of cytokines by primary human astrocytes. (A) Uptake of oligomers, (B) uptake of fibrils, (C) IL-6 release in the presence of oligomers (D) IL-6 release in the presence of fibrils, (E) MCP-1 release in the presence of oligomers, and (F) MCP-1 release in the presence of fibrils. In (A) and (B) the % fluorescent Aβ -positive cells upon incubation with either Aβ oligomers, or Aβ fibrils, was set at 100%. In (C), (D), (E) and (F) cell-responses from treated cells were compared to those of untreated cells (baseline value set at 100%; solid line). Results from five independent experiments performed with astrocyte cultures from five different donors are presented as means with standard deviation (paired t-test).
# p < 0.05 compared to untreated cells and * p < 0.05 compared to Aβ oligomer or Aβ fibril treated cells, ** p < 0.01, *** p < 0.001. and astrocytes in immunostained brain sections (Handattu et al., 2013) .
In the present study, we used mimetic peptides instead of full-length apoE and apoJ because of their potential as therapeutics for AD. Both, full-length apoE and the apoE mimetic peptide reduced Aβ oligomer uptake, although the full-length apoE was more efficient that its mimetic peptide. In addition, only apoE-MP was able to reduce Aβ fibril uptake. Full-length apoE as well as apoE-MP reduced the Aβ oligomerinduced IL-6 and MCP-1 release by the astrocytes similar to the effect observed in previous cell culture and in vivo studies (Datta et al., 2010; Vitek et al., 2012; Handattu et al., 2013) .
In a previous study, we observed an inhibitory effect of apoJ, as well as apoE, on Aβ uptake by adult human astrocytes in vitro (Mulder et al., 2014) . In the present study, apoJ-MP was found to exert similar effects as the full-length apoJ on Aβ uptake by astrocytes in vitro, although less potent. However, whereas full length apoJ enhanced Aβ-oligomer and fibril-induced IL-6 and MCP-1 release, apoJ-MP had no stimulatory effects. On the other hand, both apolipoprotein E and apoE-MP had a clear effect in reducing IL-6 and MCP-1 release, similar to the effects of apoE-MP described before on THP-1 and astroglioma U251 cells (Handattu et al., 2013) . Since apoE-MP cross the BBB (0.13% of injected dose in mice), in vivo reduce microglial and astrocytic activation, and stimulate apoE synthesis in astrocytes (Handattu et al., 2013) , the mimetic peptide holds potential as therapeutic compound.
All molecules studied inhibit Aβ oligomer uptake, whereas only apoE (full-length, as well as MP) reduces the Aβ-induced cytokine release by the astrocytes. This suggests that apoE exerts its anti-inflammatory effect by a mechanism that does not involve blocking uptake of Aβ oligomers per se. Uptake of Aβ may involve scavenger receptors, whereas Aβ-induced glial activation involves apoE-receptor LRP1 (LaDu et al., 2001) . In more recent studies, apoE was found to compete with Aβ binding to LRP1 (Verghese et al., 2013) . This may explain, why apoE inhibits Aβ uptake by adult human astrocytes (Nielsen et al., 2010; Mulder et al., 2014 ; this study), and also protects against the Aβ-induced neuroinflammatory response, resulting from receptor-mediated activation of intracellular signaling pathways.
We previously observed (Marín-Argany et al., 2011; Giménez-Llort et al., 2013) scFv-h3D6 to transform potentially synaptotoxic Aβ oligomers into harmless worm-like fibrils in vitro, and to reduce Aβ load and counteract learning and memory deficits in the 3xTg-AD mouse model. In this work, scFv-h3D6 prevented uptake of Aβ-oligomers by glial cells, and thereby may have rescued the cells from the cytotoxic and stimulatory effects of the Aβ oligomers. Because scFv-h3D6 was far more efficient than apoE-MP in preventing detrimental Aβ uptake by astrocytes and apoE-MP did not interfere with this capability, while exerting a dramatic anti-inflammatory effect, further testing of the combination holds potential. Fig. 6 . To determine possible effects on cell viability, the LDH release of astrocytes exposed to Aβ oligomers (A), and Aβ Fibrils (B) in the presence or absence of scFvh3D6 and/or MPs was compared to that of medium treated cells (set at 100%; solid line). Results from five independent experiments performed with astrocyte cultures from five different donors are presented as means and standard deviation (paired t-test). # p < 0.05, ## p < 0.01. No significant increase in LDH release was observed effects on cell viability was observed with any of the treatments.
